AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
logo

TLPH

Talphera·NASDAQ
--
--(--)
--
--(--)

Talphera (TLPH) Financials Overview

Talphera (TLPH) released its earnings on Aug 12, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.06 (YoY +40.00%), beat estimates.
Revenue / YoY
0
--
EPS / YoY
-0.06
+40.00%
Report date
Aug 12, 2026
TLPH Earnings Call Summary for Q2,2026
  • Study Momentum: NEPHRO-CRRT 75% enrolled, targeting 2026 completion. KDIGO 2026 guidelines first recommend nafamostat as regional anticoagulant.
  • Market Expansion: U.S. CRRT procedures projected at 200,000 in 2027 (+21% YoY). 70 hospitals account for 50% of procedures, driving targeted rollout.
  • Financial Position: $17.1M cash; PMA filing Q1-Q2 2027. Conditional financing ($16M) tied to study milestones. Operating expenses up 5.4% to $3.9M.
  • Commercial Strategy: Pre-PMA hires focus on medical education. 75% of U.S. hospitals lack citrate, creating adoption opportunity.

EPS

Revenue

Revenue & Expenses

Key Indicators

Talphera (TLPH) key financial stats and ratios, covering profitability, financial health, and leverage.
Talphera (TLPH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Talphera (TLPH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Talphera (TLPH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown

Where does Talphera (TLPH) generate its revenue? Explore its key revenue streams and top earning regions.

By Business

Data source:

By Region

Data source:
Track Talphera (TLPH) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History

Payout Ratio

Dividend Yield

More Financial Metrics